Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
NASDAQ:TBPH
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.1Last Year’s EPS
-0.24Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -7.05%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
Theravance Biopharma had a strong fourth quarter in 2024 with record sales in YUPELRI and significant milestone payments from TRELEGY. The company demonstrated solid progress in ampreloxetine development and maintained a strong financial position. However, potential seasonal sales declines and increased operating expenses were noted. Overall, the positive achievements and growth trajectory outweigh the concerns.Company Guidance
During the Theravance Biopharma Fourth Quarter and Full Year 2024 Conference Call, the company reported several key metrics and guidance. YUPELRI's fourth quarter net sales rose by 10% year-over-year to $66.7 million, with full-year sales reaching $239 million. Hospital doses increased by 49% year-over-year. The company also expects a $25 million U.S. sales milestone and potential income from China pending approval. TRELEGY's full-year sales by GSK reached $3.5 billion, triggering a $50 million milestone payment, with an additional $150 million possible in the next 24 months. For ampreloxetine, Theravance anticipates completing CYPRESS study enrollment by mid-2025 and plans for a New Drug Application (NDA) filing, aiming for priority review. Financial guidance for 2025 includes R&D expenses of $32-38 million and SG&A expenses of $50-60 million, with anticipated non-GAAP losses similar to 2024 levels.Record YUPELRI Net Sales
Fourth quarter YUPELRI net sales increased 10% over the fourth quarter of 2023, reaching $66.7 million, an all-time high. Hospital doses were up 49% year-over-year.
TRELEGY Sales and Milestone Achievement
GSK reported full year TRELEGY sales of $3.5 billion, up 26% year-over-year, triggering a $50 million milestone payment to Theravance.
Ampreloxetine Development Progress
Solid enrollment in the CYPRESS study and positive FDA interactions reaffirmed expectations for expedited NDA filing contingent on positive results.
Financial Position Strength
Theravance ended 2024 with $88 million in cash and no debt, excluding a recent $50 million milestone receipt.
---
TBPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TBPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $9.08 | $9.27 | +2.09% |
| Nov 12, 2024 | $8.91 | $9.68 | +8.64% |
| Aug 05, 2024 | $9.59 | $7.83 | -18.35% |
| May 13, 2024 | $9.58 | $9.39 | -1.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Theravance Biopharma (TBPH) report earnings?
Theravance Biopharma (TBPH) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Theravance Biopharma (TBPH) earnings time?
Theravance Biopharma (TBPH) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TBPH EPS forecast?
TBPH EPS forecast for the fiscal quarter 2025 (Q1) is 0.1.
---